Rotavirus vaccines in clinical development: Current pipeline and state-of-the-art

Area of Science:

• Pediatrics
• Vaccinology
• Infectious Diseases

Background:

• Rotavirus (RV) disease is a major cause of mortality and morbidity in children under five.
• Current oral rotavirus vaccines (Rotarix®, RotaTeq®) have reduced RV disease burden but face challenges.
• Limitations include reduced efficacy in low-income settings, intussusception risk, age restrictions, and cost.

Purpose of the Study:

• To review novel rotavirus vaccines currently in clinical development.
• To examine ongoing clinical trials for new RV vaccines in pediatric populations.
• To highlight strategies addressing current vaccine limitations.

Main Methods:

• Literature review of clinical development and trials for rotavirus vaccines.
• Analysis of existing rotavirus vaccine efficacy, safety, and accessibility data.
• Synthesis of information on emerging oral and parenteral rotavirus vaccine candidates.

Main Results:

• Several new oral and parenteral rotavirus vaccines are in various stages of clinical development.
• These next-generation vaccines aim to improve efficacy, safety profile, and cost-effectiveness.
• Ongoing trials are evaluating these candidates in pediatric populations worldwide.

Conclusions:

• New rotavirus vaccines hold promise for overcoming limitations of current vaccines.
• Further development and implementation are crucial for global rotavirus disease prevention.
• Advancements may lead to broader and more equitable protection against rotavirus infections in children.